Detalhe da pesquisa
1.
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy.
Blood
; 143(8): 685-696, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37976456
2.
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.
Blood
; 142(6): 553-560, 2023 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37257195
3.
Enolase 1 of Candida albicans binds human CD4+ T cells and modulates naïve and memory responses.
Eur J Immunol
; 53(11): e2250284, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37503840
4.
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG.
Eur J Nucl Med Mol Imaging
; 51(3): 749-755, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37943339
5.
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
N Engl J Med
; 382(14): 1331-1342, 2020 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32242358
6.
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Blood
; 137(6): 751-762, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929488
7.
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia.
Haematologica
; 108(7): 1758-1767, 2023 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779593
8.
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).
Br J Haematol
; 196(3): 606-616, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775591
9.
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Lancet
; 398(10299): 491-502, 2021 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097852
10.
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Blood
; 136(23): 2628-2637, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785666
11.
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(2): 223-234, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539742
12.
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Cancer
; 127(4): 554-559, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33141929
13.
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Br J Haematol
; 195(3): 388-398, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34590303
14.
Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy.
Int J Mol Sci
; 22(11)2021 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34064196
15.
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
N Engl J Med
; 376(9): 836-847, 2017 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28249141
16.
Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Blood
; 131(26): 2906-2914, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29739753
17.
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood
; 131(14): 1522-1531, 2018 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29358182
18.
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 25(8): 1498-1504, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31002989
19.
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
Cancer
; 125(23): 4181-4192, 2019 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433496
20.
Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.
Blood
; 130(18): 2027-2031, 2017 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28827408